Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 140.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 887,497 shares of the company's stock after purchasing an additional 518,300 shares during the period. Jefferies Financial Group Inc. owned about 1.97% of Apogee Therapeutics worth $40,204,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of APGE. Granahan Investment Management LLC lifted its position in shares of Apogee Therapeutics by 1.2% during the 4th quarter. Granahan Investment Management LLC now owns 92,854 shares of the company's stock worth $4,206,000 after purchasing an additional 1,097 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Apogee Therapeutics by 50.9% during the 4th quarter. Deutsche Bank AG now owns 31,739 shares of the company's stock worth $1,438,000 after purchasing an additional 10,709 shares during the last quarter. Driehaus Capital Management LLC lifted its position in shares of Apogee Therapeutics by 2.8% during the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company's stock worth $118,021,000 after purchasing an additional 71,703 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Apogee Therapeutics by 8.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 91,213 shares of the company's stock worth $4,132,000 after purchasing an additional 7,236 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Apogee Therapeutics in the fourth quarter valued at $219,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Analyst Upgrades and Downgrades

APGE has been the subject of a number of research reports. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Finally, Citigroup began coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics currently has an average rating of "Buy" and an average price target of $94.60.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the transaction, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at $38,983,558.05. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 3,860 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the completion of the sale, the insider now directly owns 247,173 shares of the company's stock, valued at $8,952,606.06. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,175 shares of company stock valued at $587,191. Company insiders own 36.10% of the company's stock.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded up $0.11 on Wednesday, hitting $39.85. The company's stock had a trading volume of 832,065 shares, compared to its average volume of 523,945. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -16.47 and a beta of 1.70. The stock has a 50 day moving average of $36.59 and a 200-day moving average of $41.39.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $0.24. Sell-side analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.